Suchergebnisse - "de Azambuja, E"

PubPharm (91)

31

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

in: OncoTargets and Therapy | 2017

von Kourie HR | El Rassy E | Clatot F | +2

32

Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

enthalten in: Cancer research | 2017

von de Azambuja, E. | Bradbury, I. | Ewer, M. | +13

33

Abstract P2-09-05: 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer

enthalten in: Cancer research | 2017

von Thürlimann, B. | Giobbie-Hurder, A. | Colleoni, M. | +16

34

Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

enthalten in: Cancer research | 2017

von Di Cosimo, S. | Appierto, V. | Tiberio, P. | +13

35

The current use and attitudes towards tumor genome sequencing in breast cancer

enthalten in: Scientific reports | 2016

von Gingras, I. | Sonnenblick, A. | de Azambuja, E. | +7

36

The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data

enthalten in: Clinical cancer research | 2016

von Bozovic-Spasojevic, I. | Zardavas, D. | Brohee, S. | +8

37

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: an international multicentre hospital-based retrospective cohort study

enthalten in: Annals of oncology | 2016

von Lambertini, M. | Pinto, A. | Ameye, L. | +12

38

Guidelines for time-to-event end point definitions in breast cancer trials : results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Gourgou-Bourgade, S. | Cameron, D. | Poortmans, P. | +42

ErratumFor: Ann Oncol. 2015 May;26(5):873-9. - PMID 25725046

39

Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Fouad, T. | de Azambuja, E. | Azim, H.

CommentOn: Ann Oncol. 2015 Feb;26(2):313-20. - PMID 25403582

40

Guidelines for time-to-event end point definitions in breast cancer trials : results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Gourgou-Bourgade, S. | Cameron, D. | Poortmans, P. | +42

ErratumIn: Ann Oncol. 2015 Dec;26(12):2505-6. - PMID 26467471